Compare Aecom (ACM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Zoetis Inc — how do they compare? Aecom trades at $62.12 (market cap $8.62B), while Zoetis Inc trades at $73.05 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 3.6× Aecom's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| ACM | ZTS | |
|---|---|---|
Market Cap | $8.62B | $31.14B |
Sector | Industrials | Health |
52-Week High | $134.35 | $156.76 |
52-Week Low | $66.86 | $71.91 |
Enterprise Value | $10.81B | $38.70B |
Dividend Yield | 1.77% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 15.32% to $62.07, driven by a Q2 2026 earnings miss with a loss of $0.50 per share versus a $1.46 estimate, alongside a securities fraud investigation announcement (Business Wire, August 11, 2026). Technical indicators are bearish, with support at $62. Despite this, revenue reached $16.14 billion in 2025, and analyst consensus remains positive with a $88.25 price target and 64% buy ratings.
The outlook is mixed: strong fundamentals like a low P/S of 0.57 and record backlog offer upside, but near-term risks from project delays and legal scrutiny may pressure the stock. Earnings volatility and negative ROE/ROA highlight execution challenges, requiring careful monitoring of quarterly results and legal developments for investor confidence.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
